Navigation Links
Swiss study suggests surgery may offer best chance of long-term prostate cancer survival
Date:10/8/2007

A study from Switzerland suggests that men who have surgery for prostate cancer appear less likely to die of the disease within 10 years than men who choose other treatment options, especially if they are younger or have cancers with certain tumor cell characteristics, according to a report in the Oct. 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Prostate cancer treatments are still being debated because they have not yet been compared in a randomized trial, in which men would be randomly assigned to one treatment or another, according to background information in the article. Therefore, treatment choice is strongly influenced by patient and physician personal preferences and experiences, the authors write.

Arnaud Merglen, M.D., of Geneva University, Switzerland, and colleagues used data from the Geneva Cancer Registry to assess all 844 patients diagnosed with localized (not yet spread) prostate cancer in Geneva between 1989 and 1998. Of those men, 158 received prostatectomy, or surgery to remove all or part of the prostate; 205 had radiation treatment (radiotherapy); 378 chose watchful waiting, which entails active follow-up and treatment if the disease progresses; 72 underwent hormone therapy; and 31 had another type of therapy.

The average follow-up was 6.7 years (range zero to 15.8 years), and 47 patients (5.6 percent) left Geneva and the study before the study concluded.

At 10 years, patients treated with radiotherapy or watchful waiting had a significantly increased risk of death from prostate cancer compared with patients who underwent prostatectomy, the authors write. Ten-year survival rates from prostate cancer were 83 percent for prostatectomy, 75 percent for radiotherapy, 72 percent for watchful waiting, 41 percent for hormone therapy and 71 percent for other treatment. The increased mortality associated with radiotherapy and watchful waiting was primarily observed in patients younger than 70 years and in patients with poorly differentiated tumors, or tumors that have certain cellular characteristics and are more likely to spread aggressively.

Until clinical trials provide conclusive evidence, physicians and patients should be informed of these results and their limitations, the authors conclude. '/>"/>

Contact: Christine Bouchardy
christine.bouchardymagnin@imsp.unige.ch
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Swiss Researchers Isolate Hair-Raising Stem Cells
2. Euthanasia To Be Permitted In Swiss Hospital
3. Swiss Group Appeals Invocation of Euthanasia Option For The Severely Depressed
4. Rural Canadians travel far for specialists: study
5. A new study surpasses Gene Therapy Hurdle
6. Tomato Sauce reduces Cancer Risk- Study
7. A question on study of Adult Stem Cell
8. Study on obesity and heart failure
9. National Lung Study in the process
10. Marijuana gateway theory strengthened by study of twins
11. Old theory of adaptation confirmed by new study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... An educational ... by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It also ... advocates, associations and industry leaders such as Bioness. , As patients feel ...
(Date:5/27/2016)... ... 2016 , ... Aimed at nurses and employees in the health care world, ... in the nursing and health care industry. It also provides insight to the developing ... , As the nursing industry is coming out of one of the biggest ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to ... Sausage Council (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of ... grilling is their favorite way to cook a hot dog, far outpacing other cooking ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... (IP) to its specialty academic programs. , Answering to the increasing demand for ... programs in health law, and environmental and land use law. ,  , “The ...
(Date:5/26/2016)... Pittsburgh, PA (PRWEB) , ... May 26, 2016 ... ... transplantation, and one that has a significant negative impact on long-term patient survival, ... to date. The results, published online this week in the Journal of Thoracic ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 2016 Hutchison China MediTech ... on the highly lucrative global oncology and immunology ... potential first-in-class or best-in-class tyrosine kinase inhibitor (TKI) ... strategic partners. HCM,s profitable Chinese healthcare business continues ... expect progress of the mid-to-late-stage pipeline during 2016-17 ...
(Date:5/27/2016)... , May 27, 2016 Amarantus ... focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, ... will be presenting at two upcoming investor conferences: ... 730 Third Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand ...
(Date:5/26/2016)... 26, 2016 According to a new ... Market - U.S. Industry Analysis, Size, Share, Growth, Trends, and ... the U.S. was valued at US$ 5.89 Bn in 2014 ... from 2015 to 2023 to reach US$ 7.99 Bn in ... and emerging needle free drug delivery devices and the market ...
Breaking Medicine Technology: